Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | DCK | P27707 | 3/20 | 0.40 |
| ▸ | FAAH | O00519 | 4/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | VCP | P55072 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928241 | 0.80 | CHRNA7 (0.60) | KDM1ACYP11B1CYP11B2 | |
| SCHEMBL27494524 | 0.79 | NPC1 (0.44) | — | |
| SCHEMBL5832681 | 0.78 | FAAH (0.40) | FAAHCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL930345 | 0.76 | CHRNB2 (0.60) | KDM1ACYP11B1CYP11B2 | |
| SCHEMBL5832709 | 0.75 | CHRNB2 (0.41) | CYP11B2 | |
| SCHEMBL5832247 | 0.75 | HTR3A (0.59) | — | |
| SCHEMBL2677658 | 0.74 | KCNH2 (0.43) | KDM1AFAAHCHRM2CHRM4CHRM5 | |
| SCHEMBL5832239 | 0.74 | CHRNA7 (0.57) | — | |
| SCHEMBL5832188 | 0.73 | MAP4K1 (0.40) | CYP11B1CYP11B2 | |
| SCHEMBL5465191 | 0.72 | HTR3A (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060699-B2 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2006-06-13 | — | — | US | disclosed |
| EP-1301514-B1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2005-01-26 | — | — | EP | disclosed |
| US-20030176416-A1 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176416-A1 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | CHRNA7, CHRNA5, CHRNA2 | KDM1A 2392/4885CYP11B1 529/4885CYP11B2 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.